Literature DB >> 31392153

The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer.

Mark D Hurwitz1.   

Abstract

Entities:  

Year:  2019        PMID： 31392153      PMCID： PMC6642962          DOI： 10.21037/tau.2019.06.09

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN： 2223-4683


× No keyword cloud information.
  15 in total

1.  Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Authors:  Karim Fizazi; Laura Faivre; François Lesaunier; Remy Delva; Gwenaëlle Gravis; Frédéric Rolland; Frank Priou; Jean-Marc Ferrero; Nadine Houede; Loïc Mourey; Christine Theodore; Ivan Krakowski; Jean-François Berdah; Marjorie Baciuchka; Brigitte Laguerre; Aude Fléchon; Alain Ravaud; Isabelle Cojean-Zelek; Stéphane Oudard; Jean-Luc Labourey; Paule Chinet-Charrot; Eric Legouffe; Jean-Léon Lagrange; Claude Linassier; Gaël Deplanque; Philippe Beuzeboc; Jean-Louis Davin; Anne-Laure Martin; Muriel Habibian; Agnès Laplanche; Stéphane Culine
Journal:  Lancet Oncol       Date:  2015-05-28       Impact factor: 41.316

2.  A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.

Authors:  Eric A Klein; Kasra Yousefi; Zaid Haddad; Voleak Choeurng; Christine Buerki; Andrew J Stephenson; Jianbo Li; Michael W Kattan; Cristina Magi-Galluzzi; Elai Davicioni
Journal:  Eur Urol       Date:  2014-11-12       Impact factor: 20.096

3.  Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

Authors:  Gwenaelle Gravis; Jean-Marie Boher; Florence Joly; Michel Soulié; Laurence Albiges; Franck Priou; Igor Latorzeff; Remy Delva; Ivan Krakowski; Brigitte Laguerre; Frédéric Rolland; Christine Théodore; Gael Deplanque; Jean-Marc Ferrero; Stéphane Culine; Loïc Mourey; Philippe Beuzeboc; Muriel Habibian; Stéphane Oudard; Karim Fizazi
Journal:  Eur Urol       Date:  2015-11-21       Impact factor: 20.096

4.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

5.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.

Authors:  R Jeffrey Karnes; Eric J Bergstralh; Elai Davicioni; Mercedeh Ghadessi; Christine Buerki; Anirban P Mitra; Anamaria Crisan; Nicholas Erho; Ismael A Vergara; Lucia L Lam; Rachel Carlson; Darby J S Thompson; Zaid Haddad; Benedikt Zimmermann; Thomas Sierocinski; Timothy J Triche; Thomas Kollmeyer; Karla V Ballman; Peter C Black; George G Klee; Robert B Jenkins
Journal:  J Urol       Date:  2013-06-11       Impact factor: 7.450

7.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola
Journal:  N Engl J Med       Date:  2015-08-05       Impact factor: 91.245

8.  Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials.

Authors:  Michael T Schweizer; Peng Huang; Michael W Kattan; Adam S Kibel; Ronald de Wit; Cora N Sternberg; Jonathan I Epstein; Mario A Eisenberger
Journal:  Cancer       Date:  2013-08-13       Impact factor: 6.860

9.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

Review 10.  Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.

Authors:  Claire L Vale; Sarah Burdett; Larysa H M Rydzewska; Laurence Albiges; Noel W Clarke; David Fisher; Karim Fizazi; Gwenaelle Gravis; Nicholas D James; Malcolm D Mason; Mahesh K B Parmar; Christopher J Sweeney; Matthew R Sydes; Bertrand Tombal; Jayne F Tierney
Journal:  Lancet Oncol       Date:  2015-12-21       Impact factor: 41.316
View more
  1 in total

1.  Nanotechnology Driven Cancer Chemoradiation: Exploiting the Full Potential of Radiotherapy with a Unique Combination of Gold Nanoparticles and Bleomycin.

Authors:  Ocean Han; Kyle Bromma; Nicholas Palmerley; Ariadne T Bido; Mesa Monica; Abdulaziz Alhussan; Perry L Howard; Alexandre G Brolo; Wayne Beckham; Abraham S Alexander; Devika B Chithrani
Journal:  Pharmaceutics       Date:  2022-01-20       Impact factor: 6.321
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.